0

NOW ENROLLING: Phase 3 SURPASS-IPF for people with idiopathic pulmonary fibrosis. Click to learn more about our clinical trial.

Skip to Content
Celea Therapeutics
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us
Celea Therapeutics
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us

ELEVATE IPF Phase 2b Results (Deupirfenidone vs. Placebo and Pirfenidone) in patients aged ≥75 years compared with <75 years. CHEST Annual Meeting. 2025. Kulkarni, T et al. [Oral Presentation]

Publication
Oct 21
Written by Christine Mackenzie
Christine Mackenzie
Previous
Previous

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

Next
Next

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

Celea Therapeutics

6 Tide Street, Suite 400
Boston, MA 02210


info@celeatx.com

DEUPIRFENIDONE
PATIENTS & PHYSICIANS
ABOUT US
CAREERS
NEWS & PUBLICATIONS
CONTACT

© 2026 Celea Therapeutics, Inc. All rights reserved. Expanded Access Policy

The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether deupirfenidone is safe and effective. No regulatory agency has made any such determination that deupirfenidone is safe or effective for use by the general public for any indication.